Financial statements are reported in EUR. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
AFMDQ — Affimed N.V.
€0.00
+€0.00 (+0.00%)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
Market Cap
€1486.25
Forward P/E
N/A
52-Week Range
N/A
AFMDQ Price History
Revenue vs. Net Income
€8.3M
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-€114M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-146.1%
ROCE · FY2023
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.5x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
45.1%
CapEx · FY2023
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+4.9%
Dilution · FY2023
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
